Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: type 1 diabetes

New Drug Approvals Hit 21-Year High in 2017

Ben Hirschler  |  January 2, 2018

LONDON (Reuters)—U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light—more than double the previous year—while the figure also rose in the European Union. The European Union (EU) recommended 92 new drugs, including generics, up from 81; and China laid out plans to speed up approvals in what…

Filed under:Drug Updates Tagged with:drugdrug approvalsdrug developmentFDAU.S. Food and Drug Administration (FDA)

What Do Diabetes, Islet Cells & Autoimmunity Have in Common?

Simon M. Helfgott, MD  |  August 15, 2017

“Man may be the captain of his fate, but he is also the victim of his blood sugar.” —Wilfrid Oakley, MB BChir, an early pioneer in diabetes care Perusing the list of the most notable medical achievements in the 20th century, a reader may conclude that the discovery of insulin should rank in a category…

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:AutoimmuneCharles BestdiabetesdiscoveryDr. Frederick Bantingglucoseinsulinislet cellsPathogenesispatient careTreatment

2016 ARHP Award Winners Discuss Their Contributions to Rheumatology

Richard Quinn  |  November 16, 2016

If you thought the presidential election was a tough choice, imagine selecting this year’s slate of ACR/ARHP award winners. At the 2016 ACR/ARHP Annual Meeting in Washington this November, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. In this issue,…

Filed under:AwardsCareer DevelopmentProfessional Topics Tagged with:AC&RACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)Association of Rheumatology Professionals (ARP)AwardsCareerdistinguished scholarhonorProfileswinners

Psoriasis May Carry Atherosclerosis Risk Similar to that with Diabetes

Kathryn Doyle  |  September 5, 2016

(Reuters Health)—People with psoriasis may be at increased risk of coronary artery calcium buildup, comparable to that of people with diabetes, according to a new study. Comparing people in their 50s with psoriasis, diabetes or neither disease, researchers found that moderate to severe calcium buildup was about five times as common in people with diabetes…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:coronary artery calciumdiabetesHeart DiseasePsoriasisrisktype II diabetes

Rheumatologists on the Move, May 2016

Ann-Marie Lindstrom  |  May 13, 2016

Associate Editor of The Rheumatologist on Working Sabbatical Maura Daly Iversen, PT, DPT, SD, MPH, professor and chair of the Department of Physical Therapy, Movement, and Rehabilitation Sciences at Northeastern University, a behavioral scientist in the Division of Rheumatology, Immunology, and Allergy at Brigham and Women’s Hospital, a lecturer at Harvard Medical School, Boston, and…

Filed under:Career DevelopmentProfessional TopicsProfiles Tagged with:Career developmentProfilesrheumatologist

2015 ACR/ARHP Annual Meeting: Genetic Links Emerge in Osteoarthritis

Thomas R. Collins  |  March 15, 2016

SAN FRANCISCO—As researchers have delved into the genetics behind osteoarthritis (OA), genes that appear to be players in the disease have emerged, but there have also been curveballs thrown, with expectations not always matching up to the genetic realities, an expert said at the 2015 ACR/ARHP Annual Meeting. The genetic risk of acquiring OA is…

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)geneticslinkOsteoarthritisResearch

2015 ACR/ARHP Annual Meeting: Stroke Risk Elevated after Herpes Zoster Infection Among Patients with Autoimmune Disease

Thomas R. Collins  |  February 16, 2016

SAN FRANCISCO—The risk of stroke after herpes zoster (HZ) infection is elevated in the period immediately after infection in patients with autoimmune diseases, according to a study presented at the 2015 ACR/ARHP Annual Meeting.1 The findings were presented in a scientific session, called Discover 2015, that highlighted new research. In another study from the session,…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)Autoimmune diseaseherpesInfectionpatient careResearchriskstroke

FDA Issues Warning for Joint Pain from Diabetes Drugs

Michele B. Kaufman, PharmD, BCGP  |  September 23, 2015

Severe and disabling joint pain has been connected to the use of dipeptidyl peptidase-4 inhibitors and combination therapies for diabetes, prompting a new FDA warning…

Filed under:Drug Updates Tagged with:adverse eventsdiabetesdrugFDAFood and Drug AdministrationJoint Pain

Rheumatologists on the Move, September 2015

Ann-Marie Lindstrom  |  September 15, 2015

Teresa Fama: Rheumatologist to Chair Public Advisory Council Teresa Fama, MD, is the new chair of the New England Comparative Effectiveness Public Advisory Council (CEPAC). A rheumatologist who practices in Berlin, Vt., Dr. Fama has previous experience in public policy, specifically health policy. Before she began her second career as a physician, Dr. Fama was…

Filed under:Career DevelopmentProfessional TopicsProfiles Tagged with:appointmentsAwardsCareerrheumatologist

FDA Warns of Severe Joint Pain Risk with DPP-4 Diabetes Drugs

Reuters Staff  |  August 31, 2015

(Reuters)—A class of diabetes drugs that include Merck & Co Inc.’s Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday. The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006,…

Filed under:Drug Updates Tagged with:FDAjointJoint Pain

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 29
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences